You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIPolo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Novel Scaffold to Promote Skin Regeneration
SBC: FirstString Research, Inc Topic: NIAMSPROJECT SUMMARY Dermal scarring affects more than million people worldwide annually over million people are injured in motor vehicle accidents over million patients are severely burned and thousands of warriors are wounded in military blasts In severe burns more than of patients develop hypertrophic scar contraction which leads to hypertrophic scar contractures HSc HSc a ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Turnkey THz Spectroscopy Polarimetry System for Pharmaceutical Applications
SBC: Microtech Instruments, Inc. Topic: 400ABSTRACT SUMMARY The outcome of this phase project will yield a turnkey system for spectroscopy polarimetry in the terahertz THz frequency range designed to support development of new drugs This system will directly probe protein vibrations using polarized terahertz radiation allowing researchers to rapidly characterize intramolecular vibrations which will help identify sites on ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of DR?1-MOG-35-55 for treatment of DR2 negative MS subjects
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: NIAIDPROJECT SUMMARY ABSTRACT Our recently completed Phaseanimal studies demonstrated the ability of our novel second generation partialp MHC constructDRhMOGto treat acute and chronic EAE with potency comparable to the parent RTLmoleculepDRMOGin matched DRTg mice and in DRnegative mismatched miceHaving met our Phasemilestonesour Phase II application will produce a fully humanized DRhMOGmolecule and ass ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
DRα MOG A Novel Immunomodulatory Therapeutic for Stroke
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: 105This is a Phase I STTR to investigate the preclinical efficacy of a novel immunomodulator DR MOG in a clinically relevant thromboembolic stroke model in mice We have previously shown that T cells are activated after stroke infiltrate brain and exacerbate ischemic brain damage Strategies that reduce T cell activation and brain tissue infiltration have been investigated as potential therapeu ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
CMV Vectored Herpes Simplex Vaccine
SBC: TOMEGAVAX, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The longterm goal of this project is to utilize cytomegalovirus (CMV) vectors in the development of a therapeutic vaccine against herpes simplex virus 2 (HSV-2), the causative agent of genital herpes. HSV-2 is widely prevalent in the population causing recurrent genital lesions and significantly increasing the risk for other sexually transmitted diseases such a ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget
SBC: DOTY SCIENTIFIC, INC. Topic: NIA? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing a Novel eHealth Application for Oral Systemic Issues during Pregnancy
SBC: InterVision Media Topic: NIDCRDESCRIPTION (provided by applicant): Oral disease is a silent epidemic because of its prevalence and missed prevention opportunities. Evidence has established connections between oral-systemic etiologies, including the effects of periodontal disease (PD), and a range of health outcomes and co-morbidities across the lifecourse (e.g., adverse pregnancy and birth outcomes; early childhood carries; ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Rapid Screening Assay for Novel Epigenetic Drugs
SBC: NZUMBE INC Topic: NIEHSDESCRIPTION (provided by applicant): A hallmark of virtually every cancer is aberrant epigenetic silencing of vital genes required for a normal cell cycle and genome stability (e.g. MLH1, BRCA1, VHL, p16, etc.). Loss of expression of these tumor suppressorgenes plays a critical role in cancer formation and growth. Thus, targeting this root cause of cancer has significant potential to treat and pot ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health